|
|
|
MIRA INFORM REPORT
|
Report No. : |
491367 |
|
Report Date : |
15.02.2018 |
IDENTIFICATION DETAILS
|
Name : |
SHIVA PHARMACHEM SA |
|
|
|
|
Registered Office : |
Hauptstrasse 64, 4132 Muttenz/BL, Switzerland/CH |
|
|
|
|
Country : |
Switzerland |
|
|
|
|
Date of Incorporation : |
25.08.2014 |
|
|
|
|
Com. Reg. No.: |
ChE-247-572-776 |
|
|
|
|
Legal Form : |
Company Limited by Shares |
|
|
|
|
Line of Business : |
The company engages in
the development, manufacture and distribution of acids, alkyl chlorides and
intermediates. The company caters to the needs of industries such as
Agrochemicals, Pharmaceutical, Polymers, Fragrance and Cosmetics. |
|
|
|
|
No. of Employees : |
1-9 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
B |
|
Credit Rating |
Explanation |
Rating Comments |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
Switzerland |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
SWITZERLAND - ECONOMIC OVERVIEW
Switzerland, a country that espouses neutrality, is a prosperous and modern
market economy with low unemployment, a highly skilled labor force, and a per
capita GDP among the highest in the world. Switzerland's economy benefits from
a highly developed service sector, led by financial services, and a
manufacturing industry that specializes in high-technology, knowledge-based
production. Its economic and political stability, transparent legal system,
exceptional infrastructure, efficient capital markets, and low corporate tax
rates also make Switzerland one of the world's most competitive economies.
The Swiss have brought their economic practices largely into conformity
with the EU's to enhance their international competitiveness, but some trade
protectionism remains, particularly for its small agricultural sector. The fate
of the Swiss economy is tightly linked to that of its neighbors in the euro
zone, which purchases half of Swiss exports. The global financial crisis of
2008 and resulting economic downturn in 2009 stalled demand for Swiss exports
and put Switzerland into a recession. During this period, the Swiss National
Bank (SNB) implemented a zero-interest rate policy to boost the economy, as
well as to prevent appreciation of the franc, and Switzerland's economy began
to recover in 2010.
The sovereign debt crises unfolding in neighboring euro-zone countries,
however, coupled with ongoing economic instability in Russia and other eastern
European economies continue to pose a significant risk to the Swiss economy,
driving up demand for the Swiss franc by investors seeking a safe-haven
currency. In January 2015, the SNB abandoned the Swiss franc’s peg to the euro,
roiling global currency markets and making active SNB intervention a necessary
hallmark of present-day Swiss monetary policy. The independent SNB has upheld
its zero interest rate policy and conducted major market interventions to
prevent further appreciation of the Swiss franc, but parliamentarians have
urged it to do more to weaken the currency. The franc's strength has made Swiss
exports less competitive and weakened the country's growth outlook; GDP growth
fell below 2% per year from 2011-17.
In recent years, Switzerland has responded to increasing pressure from
neighboring countries and trading partners to reform its banking secrecy laws,
by agreeing to conform to OECD regulations on administrative assistance in tax
matters, including tax evasion. The Swiss government has also renegotiated its
double taxation agreements with numerous countries, including the US, to
incorporate OECD standards, and is openly considering the possibility of
imposing taxes on bank deposits held by foreigners.
|
Source
: CIA |
Company
name
SHIVA PHARMACHEM SA
Operating address
Hauptstrasse 64
4132 Muttenz/BL
Switzerland/CH
Telephone: +41
329679521
Web site: http://www.shivapharmachem.com
E-mail: inquiry@shivapharmachem.eu
WIN No.: CH0010346361
VAT-No.: CHE-247.572.776 MWST
UID-No.: CHE247572776
Profile
Established: 2014
Line of Business: Pharmaceutics, Consumer goods
wholesale
Industry Division: Services, Wholesale trade
Industry-code (NACE): 7219 Other
research and experimental development on natural sciences and
engineering
4675 Wholesale of chemical products
Import/Export: Import, Export
Banks: Unknown
Operational Figures
Coverage: Company
Financial year: 2017
Employees: 1-9
Sales: CHF 2-4 Mio
Activity
The company engages in the
development, manufacture and distribution of acids, alkyl chlorides and
intermediates. The company caters to the needs of industries such as
Agrochemicals, Pharmaceutical, Polymers, Fragrance and Cosmetics.
Operations and Branches:
At the address,
Hauptstrasse 64, 4132 Muttenz, Switzerland, we find the company's registered
office.
Real Estate
Real Estate: The company does not appear to own any
property.
Company Register
Company No: ChE-247-572-776
UID-No.: CHE247572776
Legal form: Company Limited by Shares
Registration: 25.08.2014
Legal status: active
Responsible Register: Handelsregister des Kantons Basel-Landschaft
History: Date of Incorporation Statutes: 19.08.2014
Entry Deleted Name
25.08.2014 Shiva Pharmachem SA
25.08.2014 Shiva Pharmachem Ltd (Name
translated)
25.08.2014 Shiva Pharmachem AG (Name
translated)
Entry Deleted Legal
domicile
25.08.2014 Muttenz,
Switzerland
Entry Deleted Address
25.08.2014 Hauptstrasse
64, 4132 Muttenz/BL, Switzerland/CH
Entry Deleted Capital
25.08.2014 Share Capital CHF 100,000,
paid up CHF 100,000
Entry Deleted Capital
Structure
25.08.2014 100,000 Registered shares of
CHF 1.--
Official Administration
Title Name
President Agrawal, Vishal Rakesh
Citizen: India
Residential address: Vadodara / Gujarat, India
single signature
Registered since: 25.08.2014
Director Bühlmann, Karl (Charles)
Citizen: Rickenbach LU, Switzerland
Residential address: La Chaux-de-Fonds, Switzerland
single signature
Registered since: 25.08.2014
Ultimate Parent Company
Name: TASH INVESTMENT PRIVATE LIMITED
City/Country: VADODARA/Gujarat, India/IN
Direct owner/-s
No. of owner/-s: 1
Owner: The company is foreign owned.
Class: 100%, directly held
Name: SHIVA PHARMACHEM LIMITED
City/Country: Baroda/Gujarat, India/IN
Interest: 100,00% voting right, 100,00%
capital interest
Investments
It is believed that the
company has no investments.
Financials
Balance sheet
publication:
The subject company only
discloses limited financial figures.
Legal Actions
No legal actions determined
An updated legal action
check is only available against proof of interest. e.g. a copy of an enquiry
letter, and order or invoice relating to the subject company.
Sanctions List
We did not find the company
included on the various international sanctions lists, such as the OFAC (Office
of Foreign Assets Control), the BIS (Bureau of Industry and Security), the
European Union Restrictive measures (sanctions) list, the Export Control
Organisation (ECO) of the UK, the Australian Department of Foreign Affairs and
Trade.
Payment experiences
No payment history is
available.
Credit Information
Financial Statements: The company does not disclose any financial
statements. Third parties are not permitted
any insight into the
financial affairs. It is therefore difficult to make a proper assessment of the
actual situation.
Financial Situation: The financial situation is difficult to
assess.
Payment experiences: Unknown.
Credit Opinion: In advancing credit it is advised
that a bank guarantee be obtained.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 64.13 |
|
|
1 |
INR 89.17 |
|
Euro |
1 |
INR 79.39 |
|
CHF |
1 |
INR 69.08 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
PRI |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.